A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)

Learn more:

• https://clinicaltrials.gov/study/NCT04541173

Abstracts/Posters/Presentations:

• AR He, AY Kim, BM Toskich, K Mody, K Kim, S Stein, L Goyal, TA Abrams, D Brown, LW Goff, RD Kim, N Parikh, T Sandow, D Johnson, RV Iyer, M Petroziello, SS Krishnamurthi, C Martin, Y Jiang, N Akhter. A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC). Presented as a Trials in Progress Poster at the 2021 Gastrointestinal Cancers Symposium. See abstract.